1. Introduction {#sec1}
===============

Over the last decade there has been a reduction in mortality associated with B cell lymphoma due to improved recognition and treatment. Mortality is often a result of a complication of treatment or development of an infection. Fungemia carries a high risk of mortality in these immunocompromised patients \[[@bib1],[@bib2]\]. Though less frequently pathogenic than *Candida, Cyberlindnera fabianii* is a causative organism that is increasingly being recognized. It is an ascomycetous yeast of the Saccharomycetaceae family \[[@bib3]\]. Past names for the organism include: *Lindnera fabianii* and *Pichia fabianii* \[[@bib4]\]. In a review of the literature, we identified nineteen published cases or case series \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]\]. These cases noted the invasive capability of *C. fabianii*, with associated sepsis often following bacterial infection.

2. Case {#sec2}
=======

A 37-year-old male with no prior medical history was admitted to the medical ICU on day 0 with septic shock. The patient complained of a toothache on day −4, for which he went to an urgent care on day −1 and was started on amoxicillin clavulanate for a possible tooth abscess. He required vasopressor support and was placed on broad spectrum antimicrobial coverage with vancomycin, meropenem, clindamycin, and micafugin. The initial laboratory work-up was significant for neutropenia (ANC 70/μL), lactic acidosis, acute kidney injury, ischemic hepatitis (shock liver), and coagulopathy.

Due to encephalopathy, the patient required endotracheal intubation and mechanical ventilation on day 0. He was transitioned to veno-arterial ECMO on day 1 due to worsening septic shock with septic cardiomyopathy. Blood and sputum cultures from day 0 were positive for pan-susceptible *Escherichia coli*. The patient underwent three full volume plasma exchanges on days 1, 2, and 3 with stabilization in coagulation markers, progressive decline in vasopressor requirement, and clearance of lactate. Flow cytometry revealed a clonal expansion of B cells with a phenotype suggesting marginal zone lymphoma. Rituximab was started on day 8, along with intravenous methylprednisolone.The monoclonal B cell population was not present on repeat flow cytometry on day 20.

On day 16, while still on ECMO, the patient had increasing vasopressor requirements. Blood cultures from day 16 demonstrated yeast despite active treatment with micafungin, so voriconazole was added on day 19. Transthoracic echocardiography (TTE) on day 19 revealed a left ventricular apical thrombus. The yeast was initially identified as *Candida pelliculosa* by the Vitek system. Blood cultures were sent to a reference laboratory where *Cyberlindnera fabianii* was identified by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) on day 24. Amphoteracin B lipid complex was added to the antifungal regimen on day 24 due to species identification and persistent fungemia despite treatment with voriconazole and micafungin. The patient continued to require increasing vasopressor support and eventually died on day 26 after transitioning to comfort care.

3. Discussion {#sec3}
=============

In [Table 1](#tbl1){ref-type="table"} we summarize the findings of 20 cases, including our own, of *Cyberlindnera fabianii* following an English literature search \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]\]. *C. fabianii* does not appear to demonstrate a predilection for a specific age group. However, severe immunosuppression, major surgery, antimicrobial therapy, and low birth weight appear to be associated with increased propensity for infection. Prior antifungal therapy was present in 7 cases at the time of species identification, suggesting that treatment of *C. fabianii* requires proper identification and determination of susceptibility. Clinical presentation appears to be relatively nonspecific with fever being the most common presentation. Multiple cases noted nonspecific rises in C reactive protein and variable alterations in the manual differential. Based on review of our case and prior cases, no specific clinical or laboratory data are associated with new onset fungal infection with *C. fabianii*. In 12 of 20 cases (60%), fungemia was present. In all cases, specialized diagnostic testing was required to identify the correct organism. Therapies included all antifungal classes--azoles, echinocandins, formulations of amphotericin, and flucytosine---as well as source control when possible. Eight of the 20 patients (40%) died of multiple organ dysfunction syndrome.Table 1Comparison of prior published cases of *Cyberlindnera fabianii*.Table 1ReferenceAge/SexPredisposing factorsAntifungal prophylaxisSourceLab TestsDiagnostic testingTreatmentOutcomeKatagiri S, 201569/FAML s/p umbilical cord blood transplantation with preconditioning therapy, mechanical ventilation, antibacterial therapymicafunginblood culturesBeta D Glucan level (150)rRNA gene amplificationamphotericin Bmulti-organ failureH.Hof, 2017Neonate/FECMO, antibiotic prophylaxis, open heart surgery, peritoneal dialysis, mechanical ventilationfluconazoleperitoneal dialysisCRP (98)PCR analysiscaspofungin with liposomal amphotericin B, followed by fluconazolemulti-organ failureMinaric-Missoni, 20153/FNeutropenia, Leukemia, antibacterial therapyfluconazolestoolCRP (24), thrombocytopeniaPCR amplification and sequence analysisfluconazole for 5 days then inhaled amphotericin B for 14 dayssurvivedMinaric-Missoni, 20152months/MHydronephrosis, surgery, antibacterial therapynoneurineCRP (21)PCR amplification and sequence analysisfluconazole for 27 days, urinary catheter removalsurvivedMinaric-Missoni, 2015Neonate/FGastroschisis, surgery, mechanical ventilation, parenteral nutrition, antibacterial therapynoneurineCRP(123)PCR amplification and sequence analysisfluconazole for 27 days, urinary catheter removal and CVC removalsurvivedMinaric-Missoni, 2015Neonate/MHydronephrosis, surgery, parenteral nutrition, antibacterial therapynoneurineCRP (31)PCR amplification and sequence analysisfluconazole for 27 days, followed by caspofungin for 10 dayssurvivedMinaric-Missoni, 2015Neonate/FIntestinal atresia, surgery, parenteral nutrition, antibacterial therapyfluconazoleblood culturesCRP (30)PCR amplification and sequence analysisfluconazole for 15 days, CVC removalsurvivedMinaric-Missoni, 2015Neonate/FPulmonary cyst, antibacterial therapy, mechanical ventilation, parenteral nutritionfluconazoleblood culturesCRP (30), thrombocytopeniaPCR amplification and sequence analysisfluconazole for 2 days, followed by caspofungin for 21 dayssurvivedBaghdadi J, 201549/FConsumption of com ruou, ventriculoperitoneal shuntnoneCSFWBC 7810 cells/mm3 with 66.6% polymorphonuclear cellsSequencing of the D1/D2 region of the large subunit of 28S ribosomal RNA geneintravenous liposomal amphotericin B 5mg/kg daily with oral flucytosine 25mg/kg QIDsurvivedJindal N, 20145/MPreceding antitubercular treatment, ventriculoperitoneal shuntnoneurine300 leukocytes/mm3 with 24% neutrophils26S rRNA gene sequencingamphotericin Bmulti organ failureGrenouillet F, 201024 weeks/FExtremely low birth weight, antibiotic therapynoneblood cultures, pleural fluid aspiratenonspecificSequencing of 26 S ribosomal DNA and internal transcribed spacerintravenous fluconazole, followed by liposomal amphotericin B and flucytosinemulti organ failureBhally HS, 20065 week/FPremature birth (25 and 3/7 weeks)noneblood culturenon specificSequencing of D1/D2 domain of the large subunit rDNAamphotericin B, with removal of vascular cathsurvivedYun JW, 201347/FPlasma cell myeloma, lenalidomid, high dose dexamethasonenoneblood culturepancytopeniarRNA gene amplificationintravenous amphotericin B for 8 days, followed by caspofunginmulti organ failureValenza G, 200646/MMechanical ventilation, arteriovenous ECCO2R, dialysis, acute cholecystitis, antimicrobial therapynoneblood culturesnon specificGenomic DNA amplificationfluconazole, followed by caspofungin due to repeat growth in bronchmulti organ failureWu y, 201333 weeks/FPremature, LBW (1760g), peripheral venous hyperalimentation, mechanical ventilation, antimicrobial therapynoneblood culturesnon specific26S ribosomal DNA amplificationfluconazolesurvivedHamal P, 200840/MDecompressive craniotomyfluconazoleblood cultures, and infected valveelevated CRPSequencing of the ITS2 of one of the isolatesfluconazole, followed by voriconazole due to failure to clear cultures, followed by amphotericin B due to persistent fungemiasurvivedGabriel F, 201253/WAKI requiring dialysis, mesenteric ischemia, antimicrobial therapynoneoropharyngeal swab, rectal, stool cultureselevated CRPSequencing of the 18S rDNA geneIV caspofunginsurvivedLee J, 201587/MAntimicrobial therapy, hemodialysisnoneblood culturesCRP (9.65), LDH (287), leukocyte count 15,700/mm3Sequencing of the large subunit (26S) rDNA geneanidulafunginmulti organ failure secondary to relapse of bacterial infectionFernández-Ruiz, 201648/MCirrhosis, autoimmune disease, corticosteroids, rituximabnoneblood cultures, CVCnon specificPCR-based identificationcaspofunginsurvivedOur case37/MAntimicrobial therapy, ECMO, hemodialysis, mechanical ventilation, chemotherapymicafunginblood cultureselevated vasopressor requirementsMALDI-TOFmicafungin with addition of voriconazolemulti organ failure

Our patient had many of the risk factors identified in previous cases including immunosuppression (new diagnosis of B-cell lymphoma), neutropenia, chemotherapy (rituximab), mechanical ventilation, ECMO support, and antibiotic therapy (for preceding *E. coli* bacteremia). Classically, cellular immune mechanisms prevent cellular invasion by yeast with modest contribution from the humoral immune response \[[@bib1]\]. There is no clear theory to explain B-cell lymphoma or rituximab, a chimeric anti-CD20 monoclonal antibody that induces B cell depletion through lysis, phagocytosis, and cell cycle arrest, would result in increased risk of rare opportunistic fungemia. Based on prior research the influence of rituximab on fungal infections remains unclear \[[@bib19], [@bib20], [@bib21]\].

The presence of macro disruptive procedures (mechanical ventilation, ECMO, CRRT) seems to increase the likelihood of *Cyberlindnera* to cause systemic disease. Our patient presented with gram negative septic shock requiring salvage therapy with veno-arterial ECMO. Because of the high incidence and mortality of *Candida* sepsis, it is a strong recommendation of the Extracorporeal Life Support Organization (ELSO) Infectious Disease task force that clinicians lower the threshold for antifungal therapy for critically ill septic patients on ECMO \[[@bib22]\]. Our case demonstrates that we should extend this vigilance to include rare non-*Candid*a yeast species that may require different therapy in this population.

Growth of *C. fabianii* on Dalmau plate culture produces spherical ovoid budding yeast cells with occasional pseudohyphae. Microscopy demonstrates spheroidal to ellipsoidal budding blastoconidia with an absence of pseudohyphae \[[@bib3]\]. The use of routine diagnostic kits for the identification of yeast has limited ability to identify *Cyberlindnera* \[[@bib9],[@bib11],[@bib23]\]. We suspect *Cyberlindnera* infections are often undiagnosed due to a failure to complete definitive fungal identification. In our case, the organism was initially misidentified as *Candida pelliculosa* by the Vitek system. Cultures were sent to a reference lab for further identification due to the rarity of that species. Prior cases have also demonstrated misidentification as *Candida utilis* \[[@bib9]\]. Diagnosis of our yeast required use of MALDI-TOF MS.

*C. fabianii* has been described as a yeast with low virulence and a rare cause of blood stream infection and sepsis. However, our case as well as others ([Table 1](#tbl1){ref-type="table"}) have noted the organism to grow from multiple sites with a poor response to treatment with antifungal therapy. Antifungal susceptibility testing should be pursued as strains of the yeast can have varied minimum inhibitory concentrations. Prior cases also noted the rapid development of resistance in isolates following the initiation of therapy, particularly to azoles \[[@bib6],[@bib16]\]. In our case, fungemia developed while on micafungin and persisted while on both micafungin and voriconazole. Harboring of the fungus in the intra-atrial thrombus and ECMO circuit were presumably also barriers to clearance of the blood. Past *C. fabianii* isolates demonstrated strong biofilm production \[[@bib9]\], which likely contributed to the organism's persistence in ECMO recipients.

4. Conclusion {#sec4}
=============

A high index of suspicion is necessary for rare opportunistic yeast species in immunocompromised, critically ill patients, especially in those requiring life support devices such as ECMO. *Cyberlindnera fabianii* is an emerging pathogen that can be associated with fungemia, sepsis and multiple organ dysfunction syndrome. Antibiotic therapy is a risk factor, and *C. fabianii* has the ability to breakthrough antifungal prophylaxis and empiric treatment. Given that automated identification systems can misidentify this organism as a *Candida* species, we emphasize the importance of reference testing, either with MALDI-TOF MS or fungal sequencing. Accurate identification of the yeast is essential in treatment, as *Cyberlindnera* has varying antifungal susceptibilities, which must guide therapy. It requires source control due to its resistance pattern and biofilm production. In certain patients, *C. fabianii* can be highly virulent with infection resulting in considerable mortality.
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